KAM
CLDX icon

Kazazian Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Kazazian Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,405
Closed -$566K – 61
2015
Q4 		$566K Buy
2,405
+585
+32% +$128K 0.76% 21
2015
Q3 		$288K Buy
1,820
+787
+76% +$223K 0.36% 46
2015
Q2 		$391K Buy
+1,033
New +$410K 0.39% 40

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kazazian Asset Management's CLDX Position: Q1 2016 in Review

Kazazian Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 2,405 shares — an estimated $566K sold.

Kazazian Asset Management first reported a position in CLDX in Q2 2015 and held it in 3 quarters. The position peaked at $566K in Q4 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Kazazian Asset Management reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Kazazian Asset Management sold 2,405 Celldex Therapeutics shares in Q1 2016, an estimated $566K.
  • Kazazian Asset Management first reported a position in Celldex Therapeutics in Q2 2015 and held it in 3 quarters.
  • Kazazian Asset Management's Celldex Therapeutics position peaked at $566K in Q4 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Kazazian Asset Management's 13F filing for Q1 2016, filed 16 May 2016.